Nothing can kill a drug maker’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Conatus …
Today, Conatus Pharmaceuticals (NASDAQ:CNAT) share price took a hit on the announcement that the drug maker’s POLT-HCV-SVR proof-of-concept clinical trial, in liver transplant patients …
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
Oppenheimer’s Jay Olson is optimistic about CNAT’s upside potential with the forthcoming topline data from the Phase 2 POLT study.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares jumped over 9% in pre market trading to $12.98 after its New Drug Application for MM-398 was accepted for …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company’s Phase 2b clinical trial of …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment of …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that three posters addressing clinical results with emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor, have been …